Table 1.
The clinical characteristics of the rectal cancer patients
| Total n = 210 | Short‐course radiotherapy, n (%) | Long‐course radiotherapy, n (%) | Control, n (%) | |
|---|---|---|---|---|
| Sex | ||||
| Male | 119 | 54 (45) | 32 (27) | 33 (28) |
| Female | 91 | 34 (37) | 20 (22) | 37 (41) |
| Mean age (years) | 65 | 64 | 74 | |
| Preoperative Ta | ||||
| T1–2 | 48 | 27 (56) | 0 (0) | 21 (44) |
| T3 | 68 | 54 (79) | 2 (3) | 12 (18) |
| T4 | 49 | 1 (2) | 45 (92) | 3 (6) |
| Tx | 45 | 6 (13) | 5 (11) | 34 (76) |
| Postoperative Ta , b | ||||
| T1 | 10 | 3 (30) | 2 (20) | 5 (50) |
| T2 | 65 | 32 (49) | 7 (11) | 26 (40) |
| T3 | 111 | 49 (44) | 26 (24) | 36 (32) |
| T4 | 20 | 4 (20) | 13 (65) | 3 (15) |
| T0 | 4 | 0 (0) | 4 (100) | 0 (0) |
| Postoperative Na | ||||
| N0 | 124 | 51 (41) | 34 (27) | 39 (32) |
| N1 | 55 | 25 (46) | 14 (25) | 16 (29) |
| N2 | 28 | 12 (43) | 4 (14) | 12 (43) |
| Nx | 3 | 0 (0) | 0 (0) | 3 (100) |
| Postoperative stagea | ||||
| Stage I | 55 | 26 (47) | 4 (7) | 25 (46) |
| Stage II | 66 | 25 (38) | 24 (36) | 17 (26) |
| Stage III | 85 | 37 (44) | 20 (23) | 28 (33) |
| No viable tumor left | 4 | 0 (0) | 4 (100) | 0 (0) |
| Postoperative gradec | ||||
| G1 | 32 | 9 (28) | 10 (31) | 13 (41) |
| G2 | 134 | 56 (42) | 32 (24) | 46 (34) |
| G3 | 35 | 21 (60) | 3 (9) | 11 (31) |
| Gx | 9 | 2 (22) | 7 (78) | 0 (0) |
| Circumferential margin | ||||
| 0 | 18 | 3 (17) | 11 (61) | 4 (22) |
| 0≤ crm ≤2 | 21 | 8 (38) | 6 (29) | 7 (33) |
| >2 | 120 | 65 (54) | 25 (21) | 30 (25) |
| Unknown | 51 | 12 (23) | 10 (20) | 29 (57) |
| Disease‐specific outcome | ||||
| Alive without recurrence | 114 | 59 (52) | 22 (19) | 33 (29) |
| Alive with recurrence | 9 | 3 (33) | 3 (33) | 3 (33) |
| Died of disease | 56 | 16 (28) | 20 (36) | 20 (36) |
| Died of other causes | 31 | 10 (32) | 7 (23) | 14 (45) |
a
T, the extent of tumor invasion; N, nodal status, and stage according to the TNM classification of malignant tumors 16.
b
Includes the T3 tumors with threatened circumferential margin involvement.
c
Postoperative tumor differentiation grade.